You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 t-haNK

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Sep 25, 2023

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

NSCLC, Small Cell Lung Cancer, Urothelial Carcinoma Trial in United States (N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • N-803 + Pembrolizumab
  • +9 more
  • Anchorage, Alaska
  • +34 more
Apr 4, 2022

Advanced Triple Negative Breast Cancer Trial in Newport Beach (N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy)

Active, not recruiting
  • Advanced Triple Negative Breast Cancer
  • N-803
  • +3 more
  • Newport Beach, California
    Hoag Memorial Hospital
Mar 29, 2022

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises Trial in Chengdu (Dual-targeting VEGFR1 and PD-L1

Not yet recruiting
  • Malignant Peritoneal Effusion
  • +2 more
  • Dual-targeting VEGFR1 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Jul 26, 2022

Hepatocellular Carcinoma Trial in Yichang (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Sep 1, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)

Recruiting
  • Large B-cell Lymphoma
  • 89Zr-atezolizumab PET-imaging
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 15, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Monitoring T Cell Responses in Melanoma, Lung and Other Cancer

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +9 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Oct 4, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Urothelial Carcinoma Bladder
  • PD-1 Inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022

Squamous Cell Carcinoma Trial in El Segundo (drug, biological, procedure)

Unknown status
  • Squamous Cell Carcinoma
  • Aldoxorubicin HCl
  • +20 more
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Aug 10, 2020

Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

Recruiting
  • Hepatocellular Carcinoma
  • SCG101
  • PD1/PD-L1 checkpoint inhibitor
  • Beijing, China
  • +3 more
May 7, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022